



Checklist for Actemra (tocilizumab) or Biosimilar Referral

Patient Name: _____ DOB: _____ Date: _____

Referring Physician: _____ NPI: _____

Office Contact/Title/Email: _____

Office Address: _____

Office Phone: _____ Office Fax: _____

Best contact number for physician in case of reaction: _____

Please return completed checklist and checklist items to initiate referral. Use this form as fax cover sheet.

- ☐ Patient demographic information
- ☐ Insurance information and copy of insurance card/s (front and back). *Include primary and secondary insurance
- ☐ Supporting clinical notes and office visits. Two notes preferred.
 - Note should include any therapies tried/failed, and must include discussion about Actemra
 - Medication list and allergies
- ☐ Supporting lab reports/imaging for Actemra treatment
 - Baseline: Lipid panel, LFTs, neutrophils, platelets, and negative TB screening
 - *Recommended:* negative hepatitis B screening
 - For continued therapy:
 - Lipid panel 4-8 weeks after Actemra start
 - LFTs every 4-8 weeks for first 6 months after Actemra start, then every 3 months thereafter
 - Neutrophils and platelets 4-8 weeks after Actemra start, then every 3 months thereafter
- ☐ Actemra Prescribing Order (see attached)

-- We will obtain prior authorization and schedule your patient as soon as possible --

Fax all information to our Infusion Coordinator: 508-698-8671

Call with any questions: 781-551-5812 option 4

Visit our website: www.InfusionCenterNE.com

Email: info@infusioncenterne.com

Infusion Center of New England

9 Payson Road, Suite 100, Foxboro MA 02035

Ph: 781-551-5812

Fax: 508-698-8671



Prescribing Order: Actemra (tocilizumab) or Biosimilar

Date of Order: _____ ☐ New Start ☐ Maintenance
Date of last infusion: _____

Patient Name: _____ DOB: _____ M/F: _____

Diagnosis (include ICD-10 code/s): _____

☐ NKDA Allergies: _____

Patient Weight: _____

Premedication:

- | | |
|--|--|
| <input type="checkbox"/> Acetaminophen 1000mg PO | <input type="checkbox"/> Diphenhydramine 25mg IV |
| <input type="checkbox"/> Loratadine 10mg or Cetirizine 10mg PO | <input type="checkbox"/> Solu-medrol 125mg IV |
| <input type="checkbox"/> Diphenhydramine 25mg PO | <input type="checkbox"/> Other: _____ |

Lab Orders:

- | | |
|--|---|
| <input type="checkbox"/> CBC w/diff, CMP every _____ weeks | <input type="checkbox"/> LFTs every _____ weeks |
| <input type="checkbox"/> Lipid Panel 4-8 weeks after treatment start x 1 | |
| <input type="checkbox"/> Other: _____ | |

Actemra Medication Order:

- | | |
|---|---|
| <input type="checkbox"/> Infuse Actemra | <input type="checkbox"/> Infuse Actemra biosimilar as required by patient's insurance |
| Dosing: <input type="checkbox"/> 4mg/kg | <input type="checkbox"/> 8mg/kg <input type="checkbox"/> Other: _____ |
| Frequency: <input type="checkbox"/> Every 2 weeks | <input type="checkbox"/> Every 4 weeks <input type="checkbox"/> Other: _____ |

Administration:

- ✓ Mix Actemra or biosimilar in 100ml Normal Saline and administer intravenously over 1 hour.
- ✓ Do not administer if patient has active signs or symptoms of infection.
- ✓ HOLD tocilizumab if most recent ANC <2000, AST/ALT >1.5x normal limit, or platelets <100,000. Notify provider.
- ✓ In case of infusion reaction, STOP infusion and follow NCNE infusion reaction protocol. Notify provider.

Ordering Provider Name

NPI

Signature

Date

Infusion Center of New England

9 Payson Road, Suite 100, Foxboro MA 02035

Ph: 781-551-5812

Fax: 508-698-8671